Russia Cancer Vaccine 2026: What Was Actually Announced and What It Means for UK Patients

A UK explainer for May 2026. Russia announced Enteromix for colorectal cancer and Neoonkovak for melanoma. Both are personalised therapeutic mRNA vaccines, not preventive jabs. The NHS Cancer Vaccine Launch Pad runs a parallel UK programme with sites at UCLH, Leeds and other major centres.

If you were scrolling through the news in spring 2026, you might have seen a headline that caught your eye: Russia has launched a free cancer vaccine. For anyone with a relative facing bowel or skin cancer, the immediate question is simple. Can they get it and how does it compare with anything the NHS is doing?

In 2025, the Russian Federal Medical-Biological Agency announced Enteromix, a personalised mRNA vaccine for colorectal cancer, with Phase I trials starting in June 2025. Then, in April 2026, the Gamaleya Centre treated the first patient with Neoonkovak, a personalised melanoma mRNA vaccine. Russian officials say the treatments will be free for citizens under state insurance. This explainer will walk you through what the technology actually does, what the evidence shows and does not show, what the UK alternative looks like through the INTerpath-001 trial and the Cancer Vaccine Launch Pad and what a UK patient with cancer should ask their oncologist.

What Russia actually announced about Enteromix and Neoonkovak

In June 2025, the Russian Federal Medical Biological Agency began Phase I trials of Enteromix, a personalised mRNA vaccine for colorectal cancer, with 48 volunteers. The head of the FMBA, Veronika Skvortsova, said the vaccine was ready for use and awaiting regulatory approval. Russian press reports described tumour size reductions of 60 to 80 percent in early Phase I data and 100 percent efficacy in pre-clinical mouse studies.

In April 2026, a 60-year-old man from the Kursk region became the first reported recipient of Neoonkovak, a personalised melanoma mRNA vaccine from the Gamaleya Centre, the same institute that developed the Sputnik V Covid vaccine. The director of Gamaleya, Alexander Ginzburg, reported that the first patient showed cytokine changes consistent with immune activation. The Russian Health Ministry proposed adding personalised cancer vaccines to the country’s compulsory medical insurance scheme from 2026, with reports of a free supply to citizens.

None of the human data from either vaccine has been published in a peer-reviewed journal as of May 2026. The available information comes from press conferences, official statements and conference presentations. Neither vaccine has been approved for routine use even inside Russia. Phase II and III trials, with proper randomisation against standard care, would be expected before any international approval. For UK readers, the most accurate summary is that Russia has reached the human trial stage with two personalised mRNA cancer vaccines and is reporting promising but early data.

How personalised mRNA cancer vaccines actually work

A personalised cancer vaccine is not the same as a flu jab. A flu jab is preventive and the same for everyone. A personalised cancer vaccine is therapeutic, given to a patient who already has cancer and it is custom-made for that individual tumour.

The process starts with a surgery or biopsy. A sample of the tumour is genetically sequenced. Computer software then compares the tumour DNA to the patient’s normal DNA to find mutated proteins called neoantigens. These neoantigens are present on cancer cells but not on healthy cells. The most promising neoantigens are selected, often between 20 and 40 of them.

The mRNA sequence coding for those neoantigens is synthesised and packaged in lipid nanoparticles, the same delivery platform used for Covid-19 mRNA vaccines. When the vaccine is injected, the patient’s cells take up the mRNA and produce the neoantigen proteins. The immune system, especially cytotoxic T cells, learns to recognise these proteins and attacks any cell carrying them, which means the cancer cells.

These vaccines are usually given alongside an immune checkpoint inhibitor drug like pembrolizumab, which takes the brakes off the immune response. Manufacturing takes six to nine weeks per patient because every single dose is bespoke. This is why the cost per patient is high, estimated in the tens of thousands of pounds outside of clinical trials and why a broad rollout is slow. The Russian Enteromix and Neoonkovak vaccines use this same general approach, which is now the dominant strategy across the personalised cancer vaccine field, including the Moderna mRNA-4157, BioNTech BNT122 and BioNTech BNT111 programmes.

Personalised mRNA cancer vaccines use the same lipid nanoparticle delivery system as Covid-19 mRNA vaccines. Each dose is custom-made for an individual patient’s tumour over six to nine weeks.

What the evidence actually shows and what it does not

The headline figures from Russia need careful framing. The 100 percent efficacy figure is from pre-clinical animal studies, not from human trials. Pre-clinical efficacy almost never translates one-to-one to results in people. The 60 to 80 percent tumour reduction figure is from early Phase I human data, involving 48 colorectal cancer patients, with no placebo arm and no peer-reviewed publication. Phase I trials are primarily designed to test safety and to find a workable dose, not to prove efficacy.

By contrast, the most mature personalised mRNA cancer vaccine data published in a peer-reviewed journal is from the KEYNOTE-942 study. This was a Phase IIb trial of the Moderna mRNA-4157 vaccine plus pembrolizumab versus pembrolizumab alone in high-risk melanoma. At three years, the combination reduced the risk of death or cancer recurrence by 49 percent compared with pembrolizumab alone. That is the kind of randomised, peer-reviewed evidence that regulators like the MHRA want before approving a treatment and it is that figure which is now being tested in the confirmatory Phase III INTerpath-001 trial.

For Russian Enteromix and Neoonkovak, there is currently no equivalent randomised Phase II or III data. The early reports are encouraging in the same way that early-stage data is often encouraging across this field, but the absence of peer review, placebo control and independent verification means the figures should be read as preliminary signals, not confirmed results. The picture should become clearer over 2026 to 2028 as more trial data is published globally.

The UK alternative through the Cancer Vaccine Launch Pad

The UK has its own active personalised mRNA cancer vaccine programme, run as a partnership between NHS England, the Department of Health and Social Care, Genomics England and BioNTech, known as the Cancer Vaccine Launch Pad. The aim is to recruit up to 10,000 NHS cancer patients into personalised mRNA vaccine trials by 2030.

The most advanced trial under this umbrella is INTerpath-001. This is a Phase III randomised trial of the mRNA-4157 vaccine, also known as V940, in combination with pembrolizumab versus pembrolizumab alone in patients with high-risk melanoma after surgery. INTerpath-001 will enrol around 1,089 patients across multiple countries. UK sites include University College London Hospitals, the NIHR Leeds Clinical Research Facility at Leeds Teaching Hospitals and several other centres. Eligibility is typically for patients with stage 2B to 4 melanoma after complete surgical removal of the tumour.

UK patients access these trials by referral from an NHS oncologist or skin specialist, not by self-referral. The personalised vaccine is manufactured for the individual patient over six to nine weeks using their own resected tumour and dosing alongside pembrolizumab begins after surgery. Other UK trials run alongside INTerpath-001: BioNTech BNT111 for advanced melanoma, BioNTech BNT122 for colorectal cancer and similar programmes for lung, head and neck and pancreatic cancers.

None of these are routine NHS care yet. The expected timeline for any personalised mRNA cancer vaccine to become routine on the NHS is late 2027 to 2028 at the earliest, depending on trial results and MHRA approval.

Can a UK patient access the Russian vaccine

The short answer is no, not in any practical or legal sense as of May 2026. Enteromix and Neoonkovak are supplied inside Russia, under Russian state insurance, to Russian patients enrolled in clinical trials. There is no licensed UK or European supply, no MHRA approval, no recognised cross-border treatment programme and no reputable private clinic in the UK offering them. Reports of free worldwide cancer care from Russia have not been backed by any operational treatment programme that a UK patient could enrol in.

Travelling abroad for early experimental cancer therapies carries significant risks. Furthermore, manufacturing a personalised mRNA vaccine requires the patient’s tumour sample, genetic sequencing and a six to nine week production cycle. That logistics chain is difficult to set up across borders, between the UK and Russia given the current political and sanctions climate.

For a UK patient with cancer who is interested in personalised mRNA vaccines, the realistic and safe options are: ask your NHS oncologist about UK trial eligibility under the Cancer Vaccine Launch Pad, whether that is the INTerpath-001 trial or the BNT111 or BNT122 trials, depending on your cancer type. If your cancer type is not currently covered by a UK trial, ask whether a European trial might be available. Some private oncology services in the UK can help arrange referrals to trials overseas. It is important to avoid any unregulated providers who claim to offer personalised cancer vaccines outside of formal trials. Continuing with standard NHS oncology care while exploring trial options is the safest approach.

What to ask your oncologist if you are interested

If you or a relative has a cancer diagnosis and you have seen the Russian vaccine news, you can raise this with your treating oncologist in a constructive way.

First, ask whether your specific cancer type is currently covered by a UK personalised mRNA vaccine trial. The most active areas are melanoma, colorectal cancer and increasingly head and neck, lung and pancreatic cancers. Second, ask whether your cancer stage and timing make you eligible. Most of these trials recruit after primary surgery in patients with a high risk of the cancer coming back. Patients with early-stage cancers or already-treated stable disease may not fit current trial designs.

Third, ask whether the trial site is at your local NHS trust or whether you would need to travel. UK trials are clustered at large research centres including UCLH, Leeds, the Christie in Manchester, the Royal Marsden and centres in Edinburgh and Glasgow. Travel and accommodation support may be available from the trust or the trial sponsor. Fourth, ask about the treatment arms. Personalised mRNA vaccines are usually given alongside standard immunotherapy in the active arm, with the standard immunotherapy alone in the comparator arm. Both arms receive good-quality care.

Fifth, ask about the practical commitments involved. Trials typically require clinic visits every few weeks for 12 to 24 months. Be honest about what you can manage. Sixth, ask whether participation would affect your future treatment options if the experimental treatment does not work.

Frequently Asked Questions

Is the Russian cancer vaccine a preventive vaccine I can ask for

No. Enteromix and Neoonkovak are therapeutic vaccines, given to people who already have a confirmed cancer diagnosis. They are not preventive vaccines for healthy adults. The mRNA in the vaccine is coded for proteins that come from an individual’s tumour, so a vaccine made for one patient is useless for anyone else. The flu jab analogy does not apply. Healthy people in the UK cannot ask for or buy a personalised cancer vaccine in any setting as of May 2026.

What does the 100 percent efficacy claim actually mean

The 100 percent efficacy figure attached to Russian Enteromix in some news reports comes from pre-clinical animal studies, not from human trials. Pre-clinical efficacy figures are common in cancer vaccine research and almost never translate one-to-one to humans. The human Phase I trial in 48 colorectal cancer patients has reported tumour reduction of 60 to 80 percent in some cases, but this data is from a small, single-arm study that is not yet peer reviewed and should be read as preliminary.

Is there a similar vaccine available on the NHS

Not as routine care, but yes inside clinical trials. The Cancer Vaccine Launch Pad, a partnership between NHS England and BioNTech, is recruiting up to 10,000 NHS cancer patients into personalised mRNA vaccine trials by 2030. The most advanced UK trial is INTerpath-001, a Phase III study of mRNA-4157 plus pembrolizumab in high-risk melanoma after surgery, running at UCLH, Leeds and other sites. Ask your oncologist about eligibility for your cancer type.

Can I travel to Russia to get the vaccine

It is not a realistic or safe option. Enteromix and Neoonkovak are supplied to Russian patients inside clinical trials under Russian state insurance. There is no cross-border treatment programme, no MHRA approval and no licensed UK supply. Personalised vaccines require your tumour sample, sequencing and a six to nine week manufacturing cycle, which is hard to arrange across borders. UK or European trial routes are far safer and offer access to the same generation of treatment.

How is a personalised mRNA cancer vaccine different from chemotherapy

Chemotherapy uses drugs that kill rapidly dividing cells, including cancer cells and some healthy cells like those in hair follicles, bone marrow and the gut lining. A personalised mRNA cancer vaccine teaches the immune system to recognise and attack cells carrying specific tumour proteins. The two are not mutually exclusive. In current trials, mRNA vaccines are usually given alongside immune checkpoint inhibitors after surgery, with chemotherapy used separately if standard practice for that cancer type calls for it.

When might these vaccines be routine on the NHS

The most likely earliest pathway is for high-risk melanoma after surgery, depending on the Phase III INTerpath-001 readout. If the results are positive and MHRA approval follows, routine NHS availability is plausible in late 2027 to 2028. Other cancer types are further behind. UK patients should realistically expect access through clinical trials for the next two to three years than routine prescriptions and should ask their oncologist for a trial referral if interested.

What are the side effects of personalised mRNA cancer vaccines

In published trials, the most common side effects are similar to other mRNA vaccines: injection site pain or redness, fatigue, fever and flu-like symptoms in the first 48 hours after a dose. Serious side effects are uncommon in early trials. When combined with checkpoint inhibitors like pembrolizumab, there is a small added risk of immune-related side effects affecting the thyroid, skin, bowel or liver. Long-term safety data is still being collected across all current programmes.

This article is informational only and does not replace personalised advice from your GP, oncologist, or another qualified healthcare professional.